Results 211 to 220 of about 659,948 (302)

Dysregulated TIE‐2 expression is associated with blood‐brain barrier leakiness and Alzheimer's disease‐related neuropathology

Brain Pathology, EarlyView.
Ince et al., have analysed TIE‐1 and ‐2 expression in human brain tissue, including microvessel‐enriched fractions (MVF) and covering a spectrum of AD‐associated pathology, and in CSF from independent cohorts spanning a clinical spectrum from normal cognition to AD.
Selvi Ince, Carol Van Hulle, Gwendlyn Kollmorgen, Clara Quijano‐Rubio, Carey Gleason, Barbara B. Bendlin, Ozioma Okonkwo, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Sterling C. Johnson, Seth Love, J. Scott Miners   +12 more
wiley   +1 more source

Alpha-synuclein is increased in erythrocytes in parkinson's disease cases. [PDF]

Sci Rep
Coyle RN, Roberts AM, Horne M, Fowler C, Masters CL, Roberts BR.   +5 more
europepmc   +1 more source

CRYAB is compromised in pathologically affected oligodendrocytes in multiple system atrophy

Brain Pathology, EarlyView.
CRYAB is hypermethylated and colocalizes with α‐synuclein in multiple system atrophy oligodendrocytes.
Finula I. Isik, Jen‐Hsiang T. Hsiao, Felicia Xaveria Suteja, Shrey Shahdadpuri, Nicolas Dzamko, Glenda M. Halliday, Woojin Scott Kim, YuHong Fu   +7 more
wiley   +1 more source

Knockout of the LRRK2-counteracting RAB phosphatase PPM1H disrupts axonal autophagy and exacerbates alpha-synuclein aggregation. [PDF]

Cell Rep
Fricke M, Mechel A, Evers L, Twellsieck B, Grein JM, Cima-Omori MS, Al-Azzani M, Outeiro TF, Zweckstetter M, Holzbaur ELF, Boecker CA.   +10 more
europepmc   +1 more source

Lewy bodies are surrounded by granulovacuolar degeneration bodies in dementia with Lewy bodies

Brain Pathology, EarlyView.
Here, we report Lewy bodies (LBs) to be enriched for tau‐laden granulovacuolar degeneration bodies (GVBs), suggesting a potential mechanistic interface between α‐synuclein and tau pathology in dementia with Lewy bodies (DLB). Abstract Lewy bodies (LBs), composed primarily of aggregated α‐synuclein (α‐syn), are the pathological hallmark of Lewy body ...
Searlait Thom, Pawel Palmowski, Andrew Porter, Joe O'Neill, Johannes Attems, Laura A. Smith, Viktor I. Korolchuk, Daniel Erskine   +7 more
wiley   +1 more source

Biomarkers stewardship in parkinsonism: integrating alpha-synuclein seed amplification assays and neurofilament light chain into diagnostic pathways and patient communication. [PDF]

J Neurol
Leclercq V.
europepmc   +1 more source

Schedule‐dependent neuroprotection by pioglitazone in a novel model of α‐synucleinopathy in rats: Integrated behavioural and histological outcomes

British Journal of Pharmacology, EarlyView.
Background and Purpose α‐Synucleinopathies are neurodegenerative disorders characterized by the aggregation and propagation of misfolded α‐synuclein. In Parkinson's disease (PD), the most common α‐synucleinopathy, the progression of motor and nonmotor deficits, and dopaminergic neuron loss, are closely linked to the spreading of misfolded α‐synuclein ...
Alberto Santiago‐Balmaseda, Marcos M. Villegas‐Rojas, Isaac Pérez‐Segura, Maricela Espino‐Cambrón, Daniel Martinez‐Fong, Luis O. Soto‐Rojas   +5 more
wiley   +1 more source

Differential microglial responses to structurally distinct alpha-synuclein polymorphs. [PDF]

Mol Brain
Chang K, Kim J, Iba M, Park JH, Beilina A, Syed ZA, Baena V, Horan-Portelance L, Cookson MR, You S, Kim C.   +10 more
europepmc   +1 more source

SCD2 Alleviates Diabetes‐Associated Cognitive Dysfunction by Improving Microglial Lipid Metabolism

Cell Proliferation, EarlyView.
This study reveals a novel mechanism of microglial metabolic dysfunction in diabetic cognitive impairment. Defective SCD2 disrupts monounsaturated fatty acid (MUFA) metabolism, triggering mitochondrial oxidative phosphorylation dysfunction and leading to abnormal lipid droplet accumulation (marked by PLIN2).
Yang Yang, Juan He, Jing Zheng, Bing Shao, Lixin Shi, Miao Zhang   +5 more
wiley   +1 more source

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay. [PDF]

Mov Disord
Brooker SM, Pasquini J, Choi SH, Lafontant DE, Fereshtehnejad SM, Zeighami Y, Grillo P, Riboldi GM, Azizi H, Moqadam R, Kang UJ, Nudelman KNH, Siderowf A, Tanner CM, Tropea TF, Foroud T, Chahine LM, Mollenhauer B, Merchant KM, Galasko D, Coffey CS, Dobkin RD, Brown EG, Alcalay RN, Weintraub D, Marek K, Simuni T, Gonzalez-Latapi P, Pavese N, Poston KL, Parkinson's Progression Markers Initiative.   +30 more
europepmc   +1 more source